Abstract
The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19, is the defining global health crisis of our time and the greatest threat we have faced during this century [1]. According to the World Health Organizations (WHO) data, in February 2021, almost one hundred fifteen million of the population has been infected with more than two million deaths [2]. To date, in the absence of any specific treatment, our knowledge about this disease remains very limited and is subject to rapid change. This virus represents a serious danger for patients with hematologic malignancies due to myeloablative conditioning and immunosuppressive treatments. People receiving chemotherapy with compromised immune systems and complications after stem cell transplant have an increased risk for infection [3]. COVID-19 infection may complicate clinical symptoms with higher risk of respiratory distress [4]. Actually, the experience in the management of COVID-19 infection in the stem cell transplant recipients is limited.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
